FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

                                   (Mark One)
             X            Quarterly Report Pursuant to
                           Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                       For Quarter Ended: August 31, 1999
                                       OR
             _   Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                               Georgia 22-2408354
                (State or other jurisdiction of (I.R.S. Employer
               incorporation or organization) Identification No.)

                   3130 Gateway Drive P.O. Box 5625 Norcross,
                         Georgia 30091-5625 (Address of
                        principal executive offices) (Zip
                                      Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X    No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of October 1, 1999: Common Stock, $. 10 Par Value - 7,718,606

<PAGE>

                                 IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets

<TABLE>
<CAPTION>
                                                                             August 31, 1999    May 31, 1999
ASSETS                                                                        (Unaudited)          (Audited)
                                                                            ---------------     ---------------
<S>                                                                                 <C>                <C>
Current assets:
    Cash and cash equivalents                                                   $ 3,983,314         $ 2,793,592
    Accounts receivable, net                                                     20,846,263          21,573,846
    Accounts receivable from former officer and director                                  -             140,946
    Inventories                                                                  17,166,090          16,065,190
    Income taxes receivable                                                         355,642             553,451
    Deferred income taxes                                                           915,234             907,530
    Prepaid expenses and other                                                    1,248,491           1,587,817
                                                                             ---------------     ---------------
        Total current assets                                                     44,515,034          43,622,372

Long-term investment, at cost                                                     1,000,000           1,000,000

Property and equipment, at cost                                                  20,776,718          20,195,158
    less accumulated depreciation                                                (5,810,522)         (5,068,996)
                                                                             ---------------     ---------------
                                                                                 14,966,196          15,126,162

Deferred income taxes                                                             1,271,370           1,108,279

Other assets, net                                                                 2,788,156           2,934,409

Deferred licensing costs, net                                                     2,483,489           2,307,837

Excess of cost over net tangible assets acquired, net                            33,341,137          33,634,458
                                                                             ---------------     ---------------

                                                                              $ 100,365,382        $ 99,733,517
                                                                             ===============     ===============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
    Current portion of borrowings under bank line of credit agreements          $ 1,125,518         $ 1,619,312
    Current portion of long-term debt                                             4,111,313           5,000,062
    Note payable to related party                                                 1,617,739           1,637,495
    Current portion of capital lease obligations                                    194,476             194,476
    Accounts payable                                                              8,005,810          10,039,489
    Income taxes payable                                                            191,498              27,739
    Accrued salaries and wages                                                    1,065,043           1,125,216
    Deferred income taxes                                                           118,280             118,280
    Other accrued liabilities                                                     2,724,413           2,719,496
                                                                             ---------------     ---------------
        Total current liabilities                                                19,154,090          22,481,565


Long-term debt, including borrowings under bank line of credit agreements        31,183,647          30,747,855
Capital lease obligations                                                           884,843             800,117

Deferred income taxes                                                             3,079,093           3,024,550

Other liabilities                                                                 2,619,000           2,626,763

Shareholders' equity:
    Common stock, $.10 par value                                                    770,441             748,841
    Additional paid-in capital                                                   18,706,767          16,945,885
    Retained earnings                                                            26,717,867          25,498,721
    Accumulated other comprehensive loss                                         (2,750,366)         (3,140,780)
                                                                             ---------------     ---------------

        Total shareholders' equity                                               43,444,709          40,052,667
                                                                             ---------------     ---------------

                                                                              $ 100,365,382        $ 99,733,517
                                                                             ===============     ===============
</TABLE>

See accompanying notes.
<PAGE>


                                  IMMUCOR, INC.
                    Condensed Consolidated Statements of Income
                                   (Unaudited)


                                                    Three Months Ended
                                           August 31,            August 31,
                                              1999                  1998
                                         ---------------       ---------------

Net sales                                   $18,929,967          $ 10,358,465
Cost of sales                                 8,954,427             4,652,683
                                         ---------------       ---------------
Gross profit                                  9,975,540             5,705,782

Research and development                        358,688               290,027
Selling and marketing                         3,007,097             1,947,747
Distribution                                  1,535,270               562,951
General and administrative                    2,352,764             1,700,490
Merger-related expenses                          28,214                     -
Amortization expense                            460,900               142,136
                                         ---------------       ---------------
Total operating expenses                      7,742,933             4,643,351
                                         ---------------       ---------------

Income from operations                        2,232,607             1,062,431

Interest income                                   4,517               175,032
Interest expense                               (649,334)             (134,087)
Other income                                     90,054                 7,415
                                         ---------------       ---------------
Total other                                    (554,763)               48,360
                                         ---------------       ---------------

Income before income taxes                    1,677,844             1,110,791

Income taxes                                    458,698               482,780
                                         ---------------       ---------------

Net income                                  $ 1,219,146             $ 628,011
                                         ===============       ===============

Earnings per share:

     Basic                                       $ 0.16                $ 0.08
                                         ===============       ===============

     Diluted                                     $ 0.14                $ 0.08
                                         ===============       ===============


Weighted average shares outstanding:

     Basic                                    7,604,991             8,002,063
                                         ===============       ===============

     Diluted                                  8,756,946             8,283,567
                                         ===============       ===============



See accompanying notes.
<PAGE>


                                  IMMUCOR, INC.
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                   Three Months Ended
                                                                            August 31,           August 31,
                                                                               1999                 1998
                                                                          ---------------      ----------------

<S>                                                                              <C>                    <C>
OPERATING ACTIVITIES:
  Net income                                                                  $1,219,146              $628,011
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                                               535,372               368,121
      Amortization                                                               460,900               142,136
      Changes in assets and liabilities:
        Accounts receivable                                                      727,583              (241,635)
        Accounts receivable from former officer and director                     140,946               558,678
        Income tax receivable                                                    190,350                54,087
        Inventories                                                           (1,100,900)               85,838
        Other current assets                                                     373,813              (479,273)
        Accounts payable                                                      (2,033,679)              769,584
        Income taxes payable                                                     153,061               (36,297)
        Other current liabilities                                                (55,627)             (114,918)
                                                                          ---------------      ----------------

Cash provided by operating activities                                            610,965             1,734,332

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment                              (339,225)           (1,238,335)
  Cash paid for acquisitions                                                    (112,913)                    -
  Acquisition-related severance                                                  (88,961)                    -
  Decrease in other assets                                                      (261,131)                    -
                                                                          ---------------      ----------------

Cash used in investing activities                                               (802,230)           (1,238,335)

FINANCING ACTIVITIES:
  Repayment of notes payable                                                    (883,735)             (564,041)
  Exercise of stock options and warrants                                       1,782,482             1,231,444
  Purchase and retirement of stock  (478,700 shares)                                   -            (4,238,366)
                                                                          ---------------      ----------------

Cash provided by (used in) financing activities                                  898,747            (3,570,963)

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                          482,240               (41,096)
                                                                          ---------------      ----------------

INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS                               1,189,722            (3,116,062)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                               2,793,592            15,816,217
                                                                          ---------------      ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                    $3,983,314           $12,700,155
                                                                          ===============      ================

</TABLE>

See accompanying notes.

<PAGE>



                                  IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1999, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been included.  Operating  results for the three month period
ended August 31, 1999 are not necessarily  indicative of the results that may be
expected for the year ending May 31, 2000. For further information, refer to the
consolidated   financial  statements  and  footnotes  thereto  included  in  the
Company's Annual Report on Form 10-K for the year ended May 31, 1999.


2.       INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

                                     As of                          As of
                                 August 31, 1999                May 31, 1999
                               -------------------           ------------------
Raw materials and supplies             $ 4,147,425                   $3,856,309
Work in process                            851,445                      967,889
Finished goods                          12,167,220                   11,240,992
                               ===================           ==================
                                       $17,166,090                  $16,065,190
                               ===================           ==================


3.     EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.

                                                         Three Months Ended
                                                     August 31,      August 31,
                                                        1999            1998
                                                   --------------  -------------
Numerator for basic and diluted earnings per share:
  Income available to common shareholders            $1,219,146       $ 628,011
                                                   ==============  =============

Denominator:
  For basic earnings per share - weighted
  average basis                                       7,604,991       8,002,063

  Effect of dilutive stock options and warrants       1,151,955         281,504
                                                   -------------   -------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                    8,756,946       8,283,567
                                                   ============= ===============

Basic earnings per share                                  $0.16           $0.08
                                                   ============= ===============

Diluted earnings per share                                $0.14           $0.08
                                                   ============= ===============



<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):

<TABLE>
<CAPTION>

                                                          Three Months Ended August 31, 1999
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>            <C>           <C>           <C>           <C>            <C>             <C>
Net sales:
   Unaffiliated            $12,235        $2,118        $1,668        $1,082        $1,827                       $18,930
customers                                                                                       $         -
   Affiliates                1,521           101             -            72           380        (2,074)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 13,756         2,219         1,668         1,154         2,207        (2,074)         18,930

Income from operations       1,633           226           162           267           (47)           (8)          2,233

</TABLE>


<TABLE>
<CAPTION>

                                                          Three Months Ended August 31, 1998
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                           <C>            <C>           <C>           <C>           <C>            <C>             <C>
Net sales:
Net sales:
   Unaffiliated             $4,949        $2,422        $1,514        $1,186          $287                       $10,358
customers                                                                                       $         -
   Affiliates                  976            89             -            68             -        (1,133)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                  5,925         2,511         1,514         1,254           287        (1,133)         10,358

Income from operations         262           360           122           339            13           (34)          1,062

</TABLE>


During the three  months  ended  August 31, 1999 and 1998,  the  Company's  U.S.
operation  made net export  sales to  unaffiliated  customers  of  approximately
$1,748,000 and $831,000,  respectively.  The Company's German operation made net
export  sales to  unaffiliated  customers of $250,000 and $288,000 for the three
months  ended August 31, 1999 and 1998,  respectively.  The  Company's  Canadian
operation  made  export net sales to  unaffiliated  customers  of  $531,000  and
$811,000  for the three  months  ended  August 31, 1999 and 1998,  respectively.
Product sales to affiliates are valued at market prices.


5.       COMPREHENSIVE INCOME

The components of comprehensive  income for the three month periods ended August
31, 1999 and 1998 are as follows:

                                                      Three Months Ended
                                             August 31,             August 31,
                                                1999                   1998
                                         ----------------      ----------------

Net income                               $ 1,219,146               $ 628,011
Net foreign currency translation             390,414                 (53,687)
                                         ----------------      ----------------
Comprehensive income                     $ 1,609,560               $ 574,324
                                         ================      ================

Accumulated  comprehensive  loss as of  August  31,  1999  and May 31,  1999 was
($2,750,366) and ($3,140,780),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the condensed consolidated balance sheet.



<PAGE>



6.   ACCOUNTS RECEIVABLE FROM FORMER OFFICER AND DIRECTOR

In fiscal 1997, Mr. Josef Wilms,  the former  president of the Company's  German
subsidiary, Immucor GmbH, borrowed, prior to his resignation,  $300,000 from the
Company at 6% interest,  secured by his warrants to purchase  143,750  shares of
the Company's  Common Stock.  At May 31, 1998 the amount  outstanding  under the
loan was $167,000,  and as of July 14, 1998 the loan including  accrued interest
was fully paid.

In July 1997,  management  of the Company  discovered  that Mr. Wilms had caused
Immucor GmbH to make unauthorized  loans to him since 1994. The amounts advanced
were documented in the records of Immucor GmbH, including interest rates ranging
from 7.75% to 9.5%, and were  generally paid down by the end of each  accounting
period,  but  were  not  disclosed  to the  Company's  management.  The  largest
aggregate  amounts  outstanding  under the  Immucor  GmbH loans were  $29,600 in
fiscal 1994,  $290,000 in fiscal 1995,  $669,000 in fiscal 1996,  $1,311,000  in
fiscal 1997 and $528,000 in fiscal 1998.  At May 31, 1999 the amount  receivable
was  approximately  $141,000 and at August 31, 1999 the loan  including  accrued
interest was fully paid.

As of August 9, 1999 the entire unauthorized loan balance owed to the Company by
Mr. Wilms, plus accrued interest and amounts of incidental  collection  expenses
allowable under German law, had been paid to the Company. In addition, Mr. Wilms
agreed  to pay and has paid an  amount  equal  to  Immucor's  outstanding  trade
receivable totaling  approximately $320,000 from Diag Human, a company Mr. Wilms
owed  monies to, on behalf of Diag  Human.  The  remaining  collateral  has been
released to Mr. Wilms.

Mr. Wilms has had no  continuing  employment or  consulting  relationships  with
Immucor, Inc. or Immucor GmbH since December 31, 1997.


7.   CONTINGENCIES

When the Company  acquired Gamma  Biologicals,  Inc.  ("Gamma  Biologicals")  in
October 1998, Gamma Biologicals was a party to an existing legal proceeding.  On
May 12, 1998, Gamma  Biologicals  received  notification  that a claim of patent
infringement  had  been  filed on that  date in U.S.  District  Court,  Southern
District of Florida,  Miami Division, by Micro Typing Systems, Inc. and Stiftung
fur Diagnostiche Forschung (the Foundation).  Subsequently, in February 1999 the
Company received notification that a second claim was filed in the U.S. District
Court for the  Northern  District of Georgia,  against  Immucor,  Inc. and Gamma
Biologicals for patent  infringement  on the first patent  described above and a
second patent  recently  granted to the  Foundation.  The claim alleges that the
recently  introduced Gamma ReACT Test System infringes U.S. patent No. 5,512,432
granted to the Foundation April 30, 1996 and U.S. patent No.  5,863,802  granted
to the  Foundation on January 26, 1999. The  plaintiffs  seek a preliminary  and
permanent  injunction  against  the  continued  alleged  infringement  by  Gamma
Biologicals and Immucor, and an award of treble damages, with interest and costs
and reasonable  attorney's  fees.  Management is confident that ReACT technology
does not infringe the Foundation's  patents;  however, an unfavorable outcome in
this  action  could have a material  adverse  effect upon the  business  and the
results of operations in a given reporting  period.  Since this matter is in the
earliest stage of proceedings and due to  uncertainties  involved in litigation,
management  cannot  predict the likelihood of a particular  outcome.  Management
believes it has a meritorious defense against the alleged infringement.
<PAGE>


                                     IMMUCOR, INC.

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
           of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1999.

Financial Condition and Liquidity:

    During the  quarter  the  Company  increased  its  profitability,  generated
positive cash flow from operations,  and maintained positive working capital. As
of August 31, 1999,  the Company's  cash position  totaled  $3,983,000.  For the
three months ended August 31, 1999,  the Company  generated  cash from operating
activities of $611,000,  repaid $884,000 of bank debt in France, Belgium and the
U.S.  and  purchased  property  and  equipment  of  $339,000.  The  exercise  of
approximately 216,000 stock options and warrants provided $1,782,000 in cash.

     Management  believes that the Company's  current cash and cash  equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

    Net sales for the three months ended August 31, 1999 totaled $18,930,000, an
increase of $8,572,000  (83%) over last year's  $10,358,000.  Current year three
month results included  $5,052,000 in net sales from Gamma Biologicals  acquired
on October  27,  1998 and  $676,000 in net sales from  Medichim  and  Immunochim
acquired on March 15, 1999. The remaining increase in sales was generated in the
U.S. and was  primarily  due to  instrumentation  sales.  The Company  generated
instrument  revenues of $1,900,000 for the quarter  compared to $200,000 for the
same period last year.  Sales by the  Company's  Italian,  Spanish and  Portugal
subsidiaries  combined  increased  24% over last year's  total which  offset the
decrease in sales at the Company's  German and Canadian  subsidiaries of 13% and
10%, respectively.

Gross profit

    As a percent of sales,  gross  profit for the three  months ended August 31,
1999 totaled  52.7%  versus  55.1% for the same period in 1998.  The decrease in
gross profit margin was primarily caused by increased  instrument sales at lower
gross margins and the sales increase due to prior year acquisitions which are at
lower gross profit margins than Immucor's product lines.

Operating expenses

    When  compared to the prior year,  three month  period ended August 31, 1999
research  and  development  costs  increased  $69,000  with  $53,000  additional
research expense resulting from the acquisition of Gamma Biologicals.

    Selling  and  marketing  expenses  for  the  three  month  period  increased
$1,059,000 as compared to the same period last year.  Approximately  $536,000 of
the  increase  was due to the  inclusion  of prior  year  acquisitions  of Gamma
Biologicals  and  Medichim  and  Immunochim.  The  remainder  of the increase is
primarily  due to  the  effect  of  higher  payroll  expense  due to  additional
personnel required for the Company's  instrumentation  strategy and expansion of
its Spanish operation.

    Distribution expenses increased $972,000 for the three month period of which
prior year  acquisitions  account for $604,000 for the  quarter.  The  remaining
increase relates to increased shipping activity.

     General and  administrative  expenses for the three month period  increased
$652,000 with  additional  expenses of $188,000 for three months  resulting from
the purchase of Gamma  Biologicals and Medichim and Immunochim and the remainder
due to higher expenses as we expand operations worldwide.

    Merger-related   expenses  are  one-time   expenses  related  to  the  Gamma
Biologicals and BCA acquisitions.

    Amortization  expense for the three months  ended August 31, 1999  increased
$319,000 due to goodwill  recorded in the  acquisitions of Gamma  Biologicals on
October 27, 1998,  Medichim and Immunochim on March 15, 1999 and BCA, a division
of Biopool, on April 30, 1999.

Interest income

    Interest  income  decreased  $171,000  for the  quarter  due to  lower  cash
balances as compared to last year caused by the  purchase of treasury  stock and
the purchase of Gamma  Biologicals  which was partially funded by the use of the
Company's cash.

Interest expense

    When  compared  to the prior  year  three  month  period,  interest  expense
increased $515,000.  This is a result of the purchase of Gamma Biologicals which
was primarily financed with the proceeds of a bank loan.

Other income

    Other income  increased  for the three month period as compared to the prior
year due to foreign  currency  transaction  gains in the current  period  versus
losses in the same period last year.

Income taxes

    Income tax expense as a percent of pretax income, decreased during the three
month period  ended  August 31, 1999 due to lower taxes  provided in Germany and
the United  States as compared to the prior period as a result of the  Company's
ongoing implementation of tax planning strategies.


<PAGE>


Year 2000

          The  Company is aware of the issues that many  companies  will face as
the year 2000  approaches.  In order to become year 2000 compliant,  the Company
has set up a project  team to  address  the  issue  and has taken the  following
steps:

         Impact Assessment - Instances where electronics are used in the Company
and the associated  potential risks have been  identified.  The Company believes
that  non-information  technology systems and its products are not significantly
impacted.  However,  internal business information software is affected and will
require program changes in order to become year 2000 compliant.

         Third Party Impact Assessment - The Company has substantially completed
the  verification  of the readiness of its  significant  suppliers and customers
through  the  distribution  of a  questionnaire.  Although  this  process is not
complete,  based on information available,  the Company has no reason to believe
that any year 2000 problems  encountered  by customers and suppliers will have a
significant effect on the Company's operations.  The Company estimates that this
assessment will be completed by November 1999.

         Project  Plan -  Based  on the  impact  assessment,  the  need  to make
software program changes to the Company's internal business information software
has been  identified.  In Europe,  minor  software  program  changes to existing
systems are being made at a nominal cost making them year 2000 compliant  before
December  1999.  In  North   America,   the  Company  had  planned  to  complete
implementation  of a year  2000  compliant  enterprise  wide  internal  business
information  software  system by December 31, 1999. The Company is continuing to
implement the system but has decided to reschedule the  operational  date of the
new enterprise wide internal business  information  software system for February
2000.  Therefore,  the Company's initial contingency plan is now in effect under
which changes to the existing  internal business software are being made to make
it year 2000  compliant  and should be completed  by November  1999 at a cost of
approximately  $20,000  which is being  expensed  as  incurred.  The  Company is
monitoring progress closely.

         Contingency  Plan  -  The  risk  the  Company  faces  is  that  program
modifications making the existing internal business software year 2000 compliant
would not be completed by December 31, 1999.  The Company is uncertain  what the
costs  associated  with a delay  would be or the related  impact on  operations,
liquidity and financial  condition.  Because of this, the Company has in place a
contingency  plan that would allow it to continue  daily  business until program
modifications were complete.

         The Company  believes  that it is diligently  addressing  the year 2000
issue and expects that through its actions year 2000 problems are not reasonably
likely to have a material adverse effect on the Company's operations.  There can
be no assurance that such problems will not arise.

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 1999. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item 7A- Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Form 10-K.

<PAGE>


PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         27 Financial data schedule.

         (b) The  Company  did not file any reports on Form 8-K during the three
         months ended August 31, 1999.


<PAGE>

SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                                   IMMUCOR, INC.
                                                   (Registrant)



Date:  October 15, 1999








/s/  Edward L. Gallup        Edward L. Gallup, President
----------------------







/s/  Steven C. Ramsey         Steven C. Ramsey, Senior Vice President - Finance
----------------------        (Principal Accounting Officer)